This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
Special edition Themed Short Track: November/December 2019
Share |

Key messages on the New ESC/EAS Guidelines for the management of dyslipidaemias 2019

The new ESC/EAS guidelines for the management of dyslipidaemia have been recently released. Once again this complex document (comprising 78 pages of text based on 608 citations) summarizes evidence and formulates guidance of highest importance to many clinicians dealing with cardiovascular prevention both in primary care as well as in various medical specialities settings.

The first question one might ask is why it was necessary to publish these new recommendations only three years after the previous version. The primary reason is the rapidly growing evidence brought by both basic and clinical research that has helped us better understand the pathophysiology of dyslipidaemia and its role in atherogenesis. An equally important trigger for the new guidelines' publication were the results of interventional trials testing new approaches to lipid lowering, which revealed the need to revisit the question of optimal levels of lipoproteins in the plasma, and supported further decrease of the lipid goals.

We bring you four open access commentaries summarizing the highlights of the ESC/EAS guidelines by EAS contributors.



 Professor Alberico L. Catapano, one of co-chairs of the guidelines authors'  team, starts with a remark on the new concepts and basic recommendations   comprised in the document.  

 To the commentary: New recommendations and concepts in the
 new guidelines  >>


 Professor Lale Tokgozoglu, the EAS President, has dedicated her commentary to risk stratification, highlighting the importance of proper recognition and management of high- and very high-risk individuals.

 To the commentary: The approach to high - and very high-risk patients
 in the new guidelines >>


 Professor Olov Wiklund further elaborates on dyslipidaemia in special   populations.

 To the commentary: Management of dyslipidaemias in different
 clinical settings >>


 Professor Gabriele Riccardi´s contribution returns our focus to the   fundamental part of dyslipidaemia (and CVD risk) management – diet and   lifestyle factors.

 To the commentary: Important aspects related to diet and lifestyle
 in the new guidelines >>

We believe the short introductory videos will help you navigate the important changes and novel aspects of the guidelines. The full text can be read at ESC/EAS Guidelines on management of dyslipidaemia 2019 

Membership Software Powered by YourMembership  ::  Legal